ISRCTN90897064已完成未知
Targeting dopamine to treat impaired memory consolidation in neurodegenerative disease
niversity of Bristol0 个研究点目标入组 35 人开始时间: 2015年8月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37091594/ (added 24/04/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current participant inclusion criteria as of 06/07/2020:
- •1. Native or fluent English speakers (highly proficient in English language)
- •2. Normal or corrected to normal vision
- •3. Aged 65 years or older
- •4. Participants must have mental capacity to consent, and score above 11/30 in the Montreal Cognitive Assessment test
- •Previous participant inclusion criteria:
- •1. Native or fluent English speakers (highly proficient in English language)
- •2. Normal or corrected to normal vision
- •3. Aged 65 years or older (may recruit younger patients if age-matched healthy control can be found)
- •4. Diagnosis of Mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD)
- •5. Participants must have mental capacity to consent, and score above 11/30 in the Montreal Cognitive Assessment test
排除标准
- •Current exclusion criteria as of 20/04/2018:
- •1. The participants must not have:
- •1. 1. Clinically significant neurological or psychiatric diagnoses, other than MCI or mild AD for the patient group. This will be assessed by self-report and questionnaires during the screening visit
- •1.2. Known posterior cortical atrophy (mainly relevant for MCI and AD, who will have had a brain scan as a part of the diagnostic procedure)
- •1.3. Clinically significant sleep problems in the past year
- •1.4. An undiagnosed skin lesion. Participants will be asked about this.
- •1.5. Known sensitivity to levodopa, ropinirole, benserazide, or domperidone
- •1.6. Known lactose intolerance, galactosemia or glucose/galactose malabsorption
- •1.7. Known galactose intolerance
- •1.8. Known Lapp lactase deficiency
- •1.9. Diagnosis of Huntington’s Chorea
- •1.10. Intention tremor. This will be screened for by a trained investigator
- •1.11. Known prolactin-releasing pituitary tumour (prolactinoma)
- •1.12 Diagnosis of glaucoma
- •1.13 A history of, or current, malignant melanoma
- •1.14 Diagnosed diabetes
- •1.15 Known osteomalacia
- •1.16 Severe endocrine, hepatic, renal, pulmonary, or cardiac disorder
- •1.17 Diagnosed electrolyte disturbances
- •1.18 Known peptic ulcers
- •1.19 History of a heart-attack or prolongation of cardiac conduction intervals, or any other cardiac problems as taking domperidone increases risk of said problems. An ECG will be taken at the screening visit and heart-rate and blood pressure will be monitored before and after drug administration, as specified elsewhere in this protocol.
- •1.20. Current cancer treatment
- •1.21. End stage renal disease or severe renal impairment
- •1.22. Diagnosed hepatic impairment
- •1.23 Pregnant women and women of childbearing potential not using adequate contraception will
- •be excluded in line with the Madopar SmPC
- •2. The participant must not be taking:
- •2.1 Dopaminergic medications
- •2.2 Noradrenergic, serotonergic, or anticholinergic medications, except if the participant has been on stable treatment (at least 3 months) for pain or mood disorders
- •2.3 Monoamine oxidase inhibitors (MAO-I), except if selective MAO-A or MAO-B inhibitors are given. MAO-A and MAO-B inhibitors given together are equivalent to non-selective MAO-inhibition and therefore volunteers taking both MAO-A and MAO-B will not be included in this study
- •2.4. Cholinesterase inhibitors, except if the participant has been on stable treatment (at least 3 months)
- •2.5. Antihypertensive (blood pressure) drugs containing reserpine
- •2.6. Ferrous sulphate on the day of testing
- •2.7. Opioids or sympathomimetics (e.g. amphetamines, epinephrine/adrenaline)
- •2.8. Diazepam
- •2.9 Ketoconazole, erythromycin or CYP3A4 inhibitors (e.g. fluoconazole, voriconazole, clarithromycin, amiodarone, telithryomycin)
- •2.10. Antibiotics
- •2.11. Hormone replacement therapy
- •2.12. Anti-fungal agents (pentamidine)
- •2.13. Anti-malarial agents
- •2.14. Gastro-intestinal medicines
- •2.15. Antihistaminics
- •2.16. AIDS/HIV medications
- •2.17. If a participant takes antacids or antisecretory agents they should not be taken at the same time as domperidone (but these participants can be included if the medication can be taken at a different time)
- •2.18. Any medication known to interfere with co-beneldopa or domperidone
- •Original exclusion criteria:
- •1. The participants must not have:
- •1. 1. Clinically significant neurological or psychiatric diagnoses, other than MCI or mild AD for the patient group. This will be assessed by self-report and questionnaires during the
研究者
相似试验
进行中（未招募）
1 期
TARGETING DOPAMINE TO TREAT IMPAIRED MEMORY CONSOLIDATION IN NEURODEGENERATIVE DISEASE: A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAMild Cognitive ImpairmentMild Alzheimer's diseaseEUCTR2015-002027-26-GBniversity of Bristol90
已完成
2 期
DAOIB for the Treatment of Mild Cognitive ImpairmentMild Cognitive ImpairmentNCT04736355Chang Gung Memorial Hospital88
已完成
不适用
Dopaminergic Modulation of Cognition and Psychomotor FunctionDopamine ActivityEpisodic Memory ConsolidationResponse PreparationNCT01218425Maastricht University Medical Center20
尚未招募
Unknown
Effectiveness of an Online Group Memory Intervention for Neurocognitive Disorders: Pilot Studyeurocognitive DisorderNeurocognitive DisorderNeurological - Other neurological disordersACTRN12623001355662Chiara Pawela6
尚未招募
Unknown
Effectiveness of an Online Group Memory Intervention for Neurocognitive Disorders: Randomised Controlled Trial with a Waitlist ControlACTRN12623001354673Chiara Pawela48